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Abstract
Aims/hypothesis. The molecular mechanisms of obesi-
ty-related insulin resistance are incompletely under-
stood. Macrophages accumulate in adipose tissue of
obese individuals. In obesity, monocyte chemoattrac-
tant protein-1 (MCP-1), a key chemokine in the pro-
cess of macrophage accumulation, is overexpressed in
adipose tissue. MCP-1 is an insulin-responsive gene
that continues to respond to exogenous insulin in insu-
lin-resistant adipocytes and mice. MCP-1 decreases
insulin-stimulated glucose uptake into adipocytes. The
A–2518G polymorphism in the distal regulatory re-
gion of MCP-1 may regulate gene expression. The
aim of this study was to investigate the impact of this
gene polymorphism on insulin resistance.
Methods. We genotyped the Ludwigshafen Risk and
Cardiovascular Health (LURIC) cohort (n=3307). In-
sulin resistance, estimated by homeostasis model as-
sessment, and Type 2 diabetes were diagnosed in 803
and 635 patients respectively.
Results. Univariate analysis revealed that plasma
MCP-1 levels were significantly and positively cor-
related with WHR (p=0.011), insulin resistance
(p=0.0097) and diabetes (p<0.0001). Presence of the
MCP-1 G–2518 allele was associated with decreased
plasma MCP-1 (p=0.017), a decreased prevalence of
insulin resistance (odds ratio [OR]=0.82, 95% CI:
0.70–0.97, p=0.021) and a decreased prevalence of
diabetes (OR=0.80, 95% CI: 0.67–0.96, p=0.014). 
In multivariate analysis, the G allele retained statis-
tical significance as a negative predictor of insulin 
resistance (OR=0.78, 95% CI: 0.65–0.93, p=0.0060)
and diabetes (OR=0.80, 95% CI: 0.66–0.96,
p=0.018).
Conclusions/interpretation. In a large cohort of Cau-
casians, the MCP-1 G–2518 gene variant was signifi-
cantly and negatively correlated with plasma MCP-1
levels and the prevalence of insulin resistance and
Type 2 diabetes. These results add to recent evidence
supporting a role for MCP-1 in pathologies associated
with hyperinsulinaemia.
Keywords Diabetes · Insulin resistance · 
Macrophage · Monocyte chemoattractant protein-1 ·
Polymorphism
Received: 5 May 2004 / Accepted: 18 June 2004
Published online: 2 September 2004
© Springer-Verlag 2004
G. Vassalli (✉)
Department of Cardiology, University Hospital, CHUV-BH10,
1011 Lausanne, Switzerland
E-mail: giuseppe.vassalli@chuv.hospvd.ch
Tel.: +41-21-3140076, Fax: +41-21-3140013
Diabetologia (2004) 47:1574–1580
DOI 10.1007/s00125-004-1494-4
Association between the A–2518G polymorphism 
in the monocyte chemoattractant protein-1 gene 
and insulin resistance and Type 2 diabetes mellitus
E. Simeoni1, 2 · M. M. Hoffmann3 · B. R. Winkelmann4 · J. Ruiz5 · S. Fleury1, 2 · B. O. Boehm6 · W. März7 ·
G. Vassalli1, 8
1 Department of Cardiology, University Hospital, CHUV-BH10, Lausanne, Switzerland
2 Department of Experimental Surgery, University Hospital, Lausanne, Switzerland
3 Department of Clinical Chemistry, University Hospital, Freiburg, Germany
4 Cooperation Unit of Pharmacogenomics/Applied Genomics, University of Heidelberg, Germany
5 Department of Endocrinology, University Hospital, Lausanne, Switzerland
6 Division of Endocrinology and Diabetes, Department of Medicine, University Hospital, Ulm, Germany
7 Department of Clinical Chemistry, University Hospital, Graz, Austria
8 Institute of Microbiology, University Hospital, Lausanne, Switzerland
Introduction
The molecular mechanisms that link obesity and insulin
resistance are incompletely understood [1, 2, 3]. Obe-
sity, insulin resistance and diabetes mellitus share a
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homeostasis model assessment of insulin resistance · MCP-1,
monocyte chemoattractant protein-1 · MIP-1α, macrophage 
inflammatory protein-1α · NF-κB, nuclear factor-κB · PAI-1,
plasminogen-activator inhibitor-1
chronic, low-grade inflammatory component [4, 5, 6,
7], as reflected by increased expression of proinflamma-
tory cytokines such as TNF-α [8], IL-6 [9], and mono-
cyte chemoattractant protein-1 (MCP-1) [6, 7, 10, 11].
Adipose tissue functions as an endocrine organ that se-
cretes a number of biologically active proteins, includ-
ing TNF-α [8], IL-6 [6, 12], IL-8 [13], C-reactive pro-
tein, inducible nitric oxide synthase [6], TGF-β1, plas-
minogen-activator inhibitor-1 (PAI-1) [14], adiponectin
[15], resistin [16], leptin [13, 17], macrophage inflam-
matory protein-1α (MIP-1α) [7, 13] and MCP-1 [6, 7,
10, 11, 17]. Obesity alters adipose tissue endocrine
function and leads to the increased secretion of proin-
flammatory cytokines (so-called “adipokines”), hor-
mones and fatty acids [6, 7, 10]. In turn, TNF-α, IL-1β,
and other adipokines stimulate MCP-1 production and
release by human differentiated adipocytes [13].
MCP-1, which is a member of the chemokine family,
plays a key role in the recruitment of monocytes/
macrophages to inflammatory foci [18]. High glucose
directly up-regulates MCP-1 expression in vascular
endothelial cells and monocytes [19, 20]. MCP-1
mRNA is dramatically overexpressed (increased by a
factor of seven) in white adipose tissue of genetically
obese (ob/ob) mice compared with lean control mice
[10]. In these mice, the highest level of MCP-1 ex-
pression is in subcutaneous adipose tissue, with the
liver showing <10% and the kidney and lung showing
1–2% of the level of MCP-1 expression in adipose tis-
sue [10]. Insulin induces the production and secretion
of substantial amounts of MCP-1 in insulin-resistant
adipocytes and insulin-resistant obese mice [10].
MCP-1 is similar to other genes such as PAI-1 and
SREBP-1c in that it continues to respond to exogenous
insulin in insulin-resistant states [10, 21]. Moreover,
MCP-1 inhibits (by approximately 30%) insulin-stim-
ulated glucose uptake into mouse adipocytes [10].
Transcriptional profiling experiments have shown that
a number of inflammation and macrophage-enriched
or specific genes, such as MCP-1, MIP-1α, ADAM8,
MAC-1, F4/80 and CD68, are up-regulated in white
adipose tissue of mice with genetic or diet-induced
obesity [6, 7]. Of the 100 genes whose expression was
most significantly correlated with body mass, 30% en-
coded proteins that are characteristic of macrophages.
In human subcutaneous adipose tissue, both BMI and
average adipocyte size were significant predictors of
macrophage accumulation [6]. In bone marrow trans-
plant experiments in irradiated mice, 85% of the mac-
rophages that accumulated in adipose tissue after plac-
ing the mice on a high-fat diet were of bone marrow
origin [6]. In addition, in Csf1op/op mice lacking mac-
rophages, the presence of cells expressing the macro-
phage marker F4/80 in adipose tissue was greatly re-
duced compared with that in wild-type mice [6].
These findings suggest new models involving macro-
phage infiltration into adipose tissue in obesity-related
insulin resistance.
Genetic differences in chemokine expression may
contribute to differences in the severity of inflamma-
tory processes between individuals. Substantial inter-
individual variability in MCP-1 production in re-
sponse to proinflammatory cytokines has previously
been described [22, 23]. Human MCP-1 transcription
is under the control of two distinct regions within the
5’-flanking sequence of the gene. The distal region
contains two NF-κB binding sites and is essential 
for cytokine-dependent regulation, while the proximal
region contains a GC box that may regulate tissue-
specific expression [24]. A common A→G polymor-
phism located at position −2518 in the distal regulato-
ry region regulates MCP-1 expression. This was dem-
onstrated by transfection experiments in A172 and
293T cells using reporter gene constructs containing
the distal regulatory region of the MCP-1 gene with
either variant at position −2518 [22, 25]. Moreover,
MCP-1 expression in isolated, cytokine-stimulated hu-
man peripheral blood mononuclear cells [22, 25] and
hepatic cells [26], and plasma MCP-1 levels in pa-
tients with lupus nephritis support the assumption that
the gene polymorphism regulates MCP-1 expression
at the transcriptional level [25]. Case-control gene as-
sociation studies have reported statistical associations
between the polymorphism and lupus nephritis [25],
coronary artery disease (CAD) [27] and asthma [28].
The aim of the present study was to test the hypothesis
that the MCP-1 A–2518G polymorphism influences
plasma MCP-1 levels and the risk of developing insu-
lin resistance and Type 2 diabetes.
Subjects and methods
Study population and clinical definitions. We genotyped the
Ludwigshafen Risk and Cardiovascular Health (LURIC) co-
hort of 3316 individuals who underwent coronary angiography
because of chest pain or non-invasive tests consistent with
myocardial ischaemia [29]. All individuals were Caucasians
born in Germany to parents of German ancestry. Coronary ar-
tery disease was defined angiographically by a ≥20% reduction
in lumenal diameter in one or more major epicardial coronary
arteries or a 10% to 19% reduction in three or more (out of 15)
coronary artery segments. Genetic testing of this cohort was
approved by the appropriate institutional ethics committee and
informed consent was obtained from the patients. After exclud-
ing nine individuals with Type 1 diabetes, the study population
included 3307 individuals. Insulin resistance was estimated by
homeostasis model assessment (HOMAIR) [30] in the 2798 in-
dividuals who were not receiving oral hypoglycaemic drugs or
insulin treatment. The threshold for insulin resistance was de-
fined as the 90th percentile of HOMAIR distribution in individ-
uals (n=350) with no markers of the metabolic syndrome [30].
Type 2 diabetes was defined according to the new criteria of
the American Diabetes Association (ADA) and the provisional
criteria of the World Health Organization (WHO) [31, 32, 33].
Unlike in a previous study of the same cohort [34], subjects
with a single test showing a high blood glucose level, in the
absence of a confirmatory test, were not assigned an unequivo-
cal diabetes status. Older age was defined by the 50th percen-
tile of the study population.
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Assessment of plasma MCP-1 levels. Plasma MCP-1 was mea-
sured in a subgroup of 940 consecutive patients (starting from
recruitment number 1001) using the Quantikine Human MCP-1
Immunoassay (R&D Systems, Abingdon, UK). There were no
significant differences (p>0.1) between this subgroup and the
study population as a whole with respect to insulin resistance
or diabetes distribution. Blood samples were collected, pro-
cessed and stored according to the manufacturer’s instructions.
The sensitivity of the kit is approximately 0.6 pmol/l, which is
well below the lowest concentration measured in the present
study (2.9 pmol/l).
Genotyping. Genotyping of the MCP-1 A–2518G polymor-
phism was carried out by RFLP-PCR as described previously
[22]. Data are incomplete due to missing or equivocal results
in five subjects.
Statistical analysis. Data are shown as frequencies in percent
(numbers of subjects) or median values (25–75 percentiles).
The JMP program (Version 5; SAS Institute, Cary, N.C., USA)
was used for statistical analysis. Frequencies were compared
by the Cochrane–Armitage trend test. Due to skewed distribu-
tion, plasma MCP-1 data were analysed by non-parametric
tests (Wilcoxon and Kruskal–Wallis rank-sum tests). The gene
counting method estimated allele frequencies, and the chi
square test was used to test for deviations of genotype frequen-
cies from Hardy–Weinberg equilibrium. The independent con-
tributions of clinical and genetic characteristics (age, insulin
resistance, diabetes, obesity, WHR, HDL cholesterol, triglyc-
erides, hypertension, CAD and MCP-1 polymorphism) to
MCP-1 plasma levels (entered as the dependent variable) were
assessed by multivariate analysis (standard least square). The
independent contributions of the MCP-1 polymorphism to 
insulin resistance and diabetes were determined by nominal 
logistic analysis, with insulin resistance or diabetes entered as
the dependent variable, and age, sex, obesity, hypertension,
HDL cholesterol, triglycerides and WHR entered as indepen-
dent variables. In a subanalysis, diabetes was entered as a
three-class-dependent variable (encoded as no diabetes = 0,
non-insulin-treated diabetes = 1, insulin-treated diabetes = 2).
A p value (two-tailed) of less than 0.05 was considered to be
statistically significant.
Results
Clinical characteristics, insulin resistance and dia-
betes. In total, 29% (803 of 2798) of individuals who
were not on pharmacological oral hypoglycaemic
treatment had HOMAIR index values higher than or
equal to 2.96, indicating insulin resistance. Type 2 
diabetes was diagnosed in 20% (635 of 3205) of sub-
jects. Among the diabetic patients, 25% (n=161) were
on no oral hypoglycaemic drugs, 44% (n=278) were
on oral hypoglycaemic drugs and 31% (n=196) were
on insulin. Coronary angiography showed coronary
artery stenoses (lumen reduction ≥50%) in 69% of pa-
tients, minor lesions (lumen reduction <50%) in 14%
and smooth arteries in 17%. Table 1 shows the clinical
characteristics of the study population subdivided ac-
cording to insulin sensitivity or diabetes status, and
the results of univariate analysis of the clinical charac-
teristics in these subsets.
Genotype frequencies. In the population as a whole,
the frequencies of the genotypes of the A–2518G
polymorphism were: 1757 (53%) AA homozygous,
1303 (39%) GA heterozygous and 242 (7%) GG
homozygous. The genotype frequencies were in
Hardy–Weinberg equilibrium in the population as a
whole and in cases and controls defined by insulin
sensitivity or diabetes status. No differences were
found between G allele carriers (GA or GG genotype)
and non-carriers (AA genotype) with respect to age,
sex, obesity, WHR, hypertension, triglycerides or
HDL cholesterol between subsets (data not shown).
Associations between plasma MCP-1 levels and clini-
cal and genetic data. In univariate analysis, plasma
MCP-1 levels were significantly and positively corre-
lated with age, CAD and markers of the metabolic
syndrome (insulin resistance, Type 2 diabetes, hy-
pertension, obesity, WHR, high triglycerides and 
low HDL cholesterol; Table 2). In addition, plasma 
Table 1. Associations between clinical characteristics and insulin resistance and diabetes
Characteristic Insulin-sensitive Insulin-resistant p value Non-diabetic Diabetic p value
patients patientsk patients patients 
(n=1995)a (n=803)b (n=2570)c (n=635)d
Older agee 50.1 (422) 52.6 (999) 0.24 48.9 (1256) 70.2 (446) <0.0001
Sex (males) 68.7 (1370) 74.2 (596) 0.0037 70.3 (1806) 67.7 (430) 0.21
Arterial hypertensionf 53.6 (1070) 64.9 (521) <0.0001 54.6 (1404) 72.3 (459) <0.0001
High triglyceridesg 39.2 (782) 60.8 (488) <0.0001 42.8 (1100) 61.4 (389) <0.0001
Low HDL cholesterolh 47.12 (940) 61.6 (494) <0.0001 50.0 (1285) 66.8 (424) <0.0001
Obesity i 15.2 (304) 38.7 (311) <0.0001 20.2 (518) 33.20 (211) <0.0001
WHRj 72.9 (1433) 81.3 (644) <0.0001 74.1 (1875) 83.9 (533) <0.0001
Values shown are % (n). a Missing data for WHR (n=30); 
b missing data for triglycerides (n=1), HDL cholesterol (n=1)
and WHR (n=11); c missing data for HDL cholesterol (n=1)
and WHR (n=41); d missing data for triglycerides (n=1); e older
age, ≥62.7 years; f hypertension, supine systolic blood pressure
≥140 mm Hg and/or diastolic pressure ≥90 mm Hg; g high
triglycerides, ≥150 mg/ml; h low HDL cholesterol, <35 mg/ml
in males and <45 mg/ml in females; i obesity, BMI ≥30 kg/m2;
j high WHR, >0.95 in males and >0.80 in females; k insulin 
resistance, HOMAIR index ≥2.96
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MCP-1 levels were negatively correlated with the
presence of the G allele at position −2518 of MCP-1
(p=0.043 and p=0.017 for genotype and G allele car-
rier frequencies respectively; Table 3). In multivariate
analysis, age and HDL cholesterol remained associat-
ed with plasma MCP-1 (p<0.0001 and p=0.002 re-
spectively), with a trend towards statistical signifi-
cance for the MCP-1 polymorphism (p=0.06), where-
as all other associations lost statistical significance
(p>0.1).
Association between the MCP-1 A–2518G polymor-
phism and insulin resistance. The frequencies of the
MCP-1 genotypes were significantly different be-
tween insulin-sensitive and insulin-resistant subjects
(p=0.020), as were the frequencies of G allele carriers
(p=0.021; Table 3). In multivariate analysis (Table 4),
both genotype and G allele carrier frequencies re-
tained significant associations with insulin resistance
(χ2=7.56, p=0.023 and χ2=7.55, p=0.006 respec-
tively).
Association between the MCP-1 A–2518G polymor-
phism and Type 2 diabetes. Presence of the G allele
was associated with a decreased prevalence of Type 2
diabetes (p=0.014; Table 3). In multivariate analysis,
genotype and G allele carrier frequencies were signifi-
cantly associated with a decreased prevalence of dia-
betes (χ2=7.03, p=0.030 and χ2=5.62, p=0.018, re-
spectively; Table 5). The decrease in the frequency of
G allele carriers was more marked in the subgroup of
insulin-treated patients than in the subgroup of non-in-
sulin-treated diabetic patients (39% and 44% respec-
tively, vs 48% in non-diabetic individuals; χ2=7.76,
p=0.021 by three-class analysis).
Association between the MCP-1 A–2518G polymor-
phism and obesity-related insulin resistance. A sub-
group analysis revealed that, among obese patients,
the insulin-sensitive subgroup contained a higher pro-
portion of MCP-1 G–2518 carriers than the insulin-
resistant subgroup (52.5% vs 43.9%; p=0.04). Similar-
ly, obese individuals who did not develop Type 2 dia-
Table 2. Associations between plasma MCP-1 levels and clinical characteristics
Group n Plasma MCP-1 (pmol/l) p value
Younger 419 16.3 (13.7–19.9) <0.0001
Older 521 19.2 (15.6–23.6)
No CAD 170 16.8 (14.1–20.2) 0.005
CAD 738 17.9 (14.8–23.6)
Insulin-sensitive 573 17.1 (14.4–20.9) 0.0097
Insulin-resistant 211 18.2 (15.1–22.2)
Non-diabetic 729 17.2 (14.4–21.0) <0.0001
Diabetic 177 20.3 (15.9–25.9)
Normotensive 409 17.2 (14.3–21.0) 0.016
Hypertensive 531 18.2 (14.9–22.6)
Normal triglycerides 496 17.1 (14.1–21.0) 0.0010
High triglycerides 444 18.5 (15.1–23.0)
Normal HDL cholesterol 440 17.1 (14.0–20.7) <0.0001
Low HDL cholesterol 499 18.5 (15.2–23.3)
Lean 690 17.5 (14.5–21.7) 0.042
Obese 250 18.5 (15.3–22.3)
Normal WHR 231 16.9 (14.0–20.8) 0.011
High WHR 708 18.0 (14.8–22.4)
Values are medians (25–75 percentiles). Missing data for CAD (n=32), diabetes status (absence of confirmatory test; n=34), HDL
cholesterol (n=1) and WHR (n=1)
Table 3. Associations between the MCP-1 polymorphism and plasma MCP-1 levels, insulin resistance and diabetes
Group Genotype p value G allele carriers p value
AA AG GG
Plasma MCP-1 (pmol/l)a 18.2 (15.2–22.4) 17.4 (14.4–21.4) 17.1 (13.7–21.5) 0.043 17.2 (14.4–21.4) 0.017
Insulin-sensitive 51.1 (1018) 41.4 (826) 7.5 (150) 0.020 49.0 (976) 0.021
Insulin-resistant 55.9 (448) 37.9 (304) 6.2 (50) 44.1 (354)
Non-diabetic 52.0 (1335) 40.6 (1043) 7.4 (190) 0.053 48.0 (1233) 0.014
Diabetic 57.4 (363) 35.1 (222) 7.4 (47) 42.6 (269)
Values are % (n) unless otherwise indicated. a Values are medians (25–75 percentiles)
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betes were more likely to be G allele carriers than
those who became diabetic (48.5% vs 40.5%; p=0.06).
Plasma MCP-1 levels were significantly increased in
obese diabetic patients compared with those in obese
non-diabetic patients (21.4 vs 17.6 pmol/l; p<0.05).
Discussion
There is increasing evidence that MCP-1, a potent
chemoattractant of monocytes/macrophages, partici-
pates in metabolic activities that involve regulation of
adipose tissue functions, inhibition of insulin-stimu-
lated glucose uptake into adipocytes [10] and accumu-
lation of macrophages in adipose tissue in obese hu-
mans [6]. In search of genetic factors that affect insu-
lin resistance, we investigated the role of the common
MCP-1 A–2518G polymorphism, which may regulate
MCP-1 expression at the transcriptional level [22, 25,
26]. In a large cohort of Caucasians with a high preva-
lence of cardiovascular risk factors, we found de-
creased plasma MCP-1 levels and a decreased preva-
lence of insulin resistance and Type 2 diabetes in car-
riers of the G allele compared with subjects homozy-
gous for the frequent A allele. A protective role for
this genetic variant is supported by the finding that,
among obese patients, the frequency of G allele carri-
ers was increased in those with preserved insulin sen-
sitivity. In multivariate analysis, the G allele remained
significantly and negatively correlated with insulin re-
sistance and diabetes after correction for risk factors
identified by univariate analysis (including CAD).
The decrease in G allele frequency was more pro-
nounced among insulin-treated patients than among
non-insulin-treated diabetic patients, suggesting that
the role of the gene polymorphism may become more
manifest at later stages of the disease.
Our findings of decreased plasma MCP-1 levels in
carriers of the G allele are in agreement with data in
patients with lupus nephritis [25]. In the present study,
plasma MCP-1 levels were significantly and positive-
ly correlated with markers of the metabolic syndrome,
such as insulin resistance, Type 2 diabetes, hyperten-
sion, obesity, WHR, high triglycerides and low HDL
Table 4. Nominal logistic fit, with insulin resistance entered as the dependent variable
Genotype analysis G allele carriers analysis
Source of variation df r2 χ2 p value df r2 χ2 p value OR (95% CI)
All variables 9 0.09 301.28 <0.0001 8 0.09 301.27 <0.0001
Older age 1 7.60 0.0058 1 7.62 0.0058 1.29 (1.08–1.54)
Male sex 1 17.77 <0.0001 1 17.83 <0.0001 1.56 (1.27–1.92)
Hypertension 1 5.52 0.019 1 5.51 0.019 1.25 (1.04–1.50)
High triglycerides 1 52.99 <0.0001 1 53.06 <0.0001 1.96 (1.64–2.35)
Low HDL cholesterol 1 21.99 <0.0001 1 21.97 <0.0001 1.55 (1.29–1.86)
Obesity 1 116.19 <0.0001 1 116.19 <0.0001 3.00 (2.45–3.66)
High WHR 1 5.01 0.025 1 5.02 0.025 1.29 (1.03–1.62)
MCP-1 A–2518G 2 7.56 0.023 1 7.55 0.0060 0.78 (0.65–0.93)
polymorphism
In this multivariate model, n=2753 due to incomplete data. df: 2 for genotype three-class analysis (encoded as AA=0, AG=1,
GG=2), 1 for G allele carrier two-class analysis (encoded as AA=0, AG+GG=1). OR, odds ratio
Table 5. Nominal logistic fit, with Type 2 diabetes entered as the dependent variable
Genotype analysis G allele carriers analysis
Source of variation df r2 χ2 p value df r2 χ2 p value OR (95% CI)
All variables 9 0.09 291.73 <0.0001 8 0.09 290.26 <0.0001
Older age 1 88.33 <0.0001 1 88.81 <0.0001 2.60 (2.13–3.17)
Male sex 1 2.08 0.15 1 2.15 0.14 1.17 (0.95–1.44)
Hypertension 1 26.50 <0.0001 1 26.45 <0.0001 1.70 (1.39–2.08)
High triglycerides 1 43.45 <0.0001 1 42.80 <0.0001 1.90 (1.57–2.30)
Low HDL cholesterol 1 28.88 <0.0001 1 28.86 <0.0001 1.71 (1.41–2.09)
Obesity 1 21.69 <0.0001 1 21.49 <0.0001 1.63 (1.32–2.00)
High WHR 1 5.13 0.024 1 5.08 0.024 1.33 (1.03–1.71)
MCP-1 A–2518G 2 7.03 0.030 1 5.62 0.018 0.80 (0.66–0.96)
polymorphism
In this multivariate model, n=3247 due to incomplete data. df: 2 for genotype three-class analysis (encoded as AA=0, AG=1,
GG=2), 1 for G allele carrier two-class analysis (encoded as AA=0, AG+GG=1). OR, odds ratio
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cholesterol, according to univariate analysis. These re-
sults are consistent with previous data in patients with
Type IIa and IIb hyperlipoproteinaemia [35]. More-
over, we observed increased plasma MCP-1 levels in
patients with Type 2 diabetes, corroborating previous
data from the Orbofiban in Patients With Unstable
Coronary Syndromes—Thrombolysis In Myocardial
Infarction (OPUS-TIMI) 16 trial and from a cohort of
women with glucose intolerance [36, 37]. Conversely,
another study showed that insulin infusion results in
decreased plasma MCP-1 levels in obese subjects [38].
Macrophage accumulation in human subcutaneous
adipose tissue increases with increasing obesity and
adipocyte size [6]. In obesity, infiltrating macrophages
account for almost all TNF-α expression and a signifi-
cant proportion of the expression of other inflammato-
ry mediators in adipose tissue [6]. Interestingly, the
epicardial adipose tissue of patients with CAD pro-
duces increased amounts of MCP-1, TNF-α, IL-1β,
and IL-6 compared with epicardial adipose tissue of
subjects without CAD, suggesting that regional adi-
pose tissue may be a source of atherogenic proinflam-
matory molecules [39].
The molecular mechanism by which the polymor-
phism regulates MCP-1 gene transcription is unclear.
Although it is located in the distal regulatory region of
the gene that contains two NF-κB binding sites essen-
tial for cytokine-stimulated gene transcription [24],
the polymorphism does not alter the sequence of the
NF-κB sites. Electrophoretic mobility shift assays
have suggested that the binding site for an as yet
unidentified transcription factor might be altered [22].
We propose that decreased MCP-1 expression in carri-
ers of the G allele may prevent the pathogenic vicious
circle by which MCP-1 expression promotes macro-
phage accumulation in adipose tissue, TNF-α release
by macrophages, TNF-α-stimulated MCP-1 expres-
sion and MCP-1-mediated antagonism of insulin ac-
tivities in this tissue. Similarly, a single-nucleotide
polymorphism in the promoter of the gene encoding
resistin, an adipocyte-secreted hormone, has been
linked to insulin resistance in humans [40].
In conclusion, we have reported, for the first time,
that the MCP-1 G–2518 allele is significantly and
negatively correlated with circulating MCP-1 levels,
insulin resistance and Type 2 diabetes. Replication 
of the reported genetic associations in independent 
cohorts are needed to validate the role of the polymor-
phism in the development of insulin resistance.
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